A Phase 2, Double-Blind, Multi-Center, Placebo-Controlled Clinical Study to Evaluate the Safety, Tolerability, Efficacy, and Pharmacokinetics of FHL-301 in Adult Patients With Parkinson's Disease
Latest Information Update: 13 Feb 2025
Price :
$35 *
At a glance
- Drugs Gemfibrozil (Primary)
- Indications Parkinson's disease
- Focus Therapeutic Use
- Sponsors Forest Hills Lab
- 10 Feb 2025 Planned End Date changed from 30 Dec 2024 to 1 Nov 2028.
- 10 Feb 2025 Planned primary completion date changed from 1 Dec 2024 to 1 Nov 2028.
- 10 Feb 2025 Planned initiation date changed from 1 Nov 2024 to 1 Nov 2027.